Undervalued Biotech's

Description:

With the merger between Pfizer (PFE) and Wyeth (WYE), the attempted takeover of Genentech (DNA) by Roche, and the overall positive action in Amgen (AMGN), Celgene Corp (CELG), Genzyme (GENZ), and Geilead (GILD) recently, many analysts and investors believe that 2009 will be a positive year for the biotech industry as a whole.
Important events in the biotech space include Dendreon’s (DNDN) binary data announcement on its key drug Provenge in early April and Genentech’s (DNA) update on various uses for Avastin late April.

Most Viewed Portfolios

View All

Articles

5 Large-Cap Stocks to Trade for Earnings Season Gains

07.24.14 | 10:40 AM

BALTIMORE (Stockpickr) -- The S&P 500 pushed its way into new highs yesterday, ending Wednesday's session at a new record once again. That new high...

3 Stocks Spiking on Big Volume

07.24.14 | 09:12 AM

DELAFIELD, Wis. (Stockpickr) -- Professional traders running mutual funds and hedge funds don't just look at a stock's price moves; they also trac...

More Articles
blog comments powered by Disqus
brokerage partners
connect with Stockpickr
Fan us on FaceBook
Follow us on Twitter